Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics

Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova*, Valeria I. Gerasimova, Alexander N. Kornetov, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)
79 Downloads (Pure)

Abstract

The present study aims at comparing the change in cytokine levels in schizophrenia patients treated with atypical antipsychotics, with or without metabolic syndrome (MetS). The study included 101 patients with schizophrenia, 38 with and 63 without MetS, who received risperidone, quetiapine, olanzapine or aripiprazole for six weeks. We analyzed the concentration of 21 cytokines in the serum patients. The treatment with atypical antipsychotics changed some proinflammatory cytokine levels. It led to increased IFN-alpha 2 (p = 0.010), IL-1 alpha (p = 0.024) and IL-7 (p = 0.017) levels in patients with MetS, whereas the same treatment led to decreased levels of IFN-gamma (p = 0.011), IL-1 beta (p = 0.035), IL-12p40 (p = 0.011), IL-17A (p = 0.031), IL-6 (p = 0.043) and TNF-alpha (p = 0.012) in individuals without MetS. Our results demonstrated the effects of atypical antipsychotics on the immune-inflammatory parameters, depending on the metabolic disturbances in schizophrenia patients.

Original languageEnglish
Article number446
Number of pages11
JournalPharmaceuticals
Volume14
Issue number5
DOIs
Publication statusPublished - May-2021

Keywords

  • schizophrenia
  • atypical antipsychotics
  • cytokine
  • metabolic syndrome
  • INFLAMMATORY CYTOKINES
  • DRUG
  • PREVALENCE
  • MECHANISMS
  • IL-17

Fingerprint

Dive into the research topics of 'Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics'. Together they form a unique fingerprint.

Cite this